{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:25:15Z","timestamp":1793384715990,"version":"4.5.0"},"reference-count":66,"publisher":"S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMedLife"],"abstract":"<jats:p>Neuromuscular junction (NMJ) disorders include several dysfunctions that ultimately lead to muscle weakness. Myasthenia gravis (MG) is the most prevalent NMJ disorder with a highly polymorphic clinical presentation and many different faces. Being an autoimmune disease, MG correlates with the presence of detectable antibodies directed against the acetylcholine receptor, muscle-specific kinase, lipoprotein-related protein 4, agrin, titin, and ryanodine in the postsynaptic membrane at the NMJ. MG has become a prototype serving to understand both autoimmunity and the function of the NMJ better. The aim of this review is to synthesize some of the epidemiological data available. Epidemiological data regarding MG are important for postulating hypotheses regarding its etiology and facilitating the description of MG subtypes. Thus, adequate documentation through broad databases is essential. The incidence and prevalence of MG reported around the globe have been rising steadily and consistently over the past decades. Ethnic aspects, gender-related differences, and environmental risk factors have been described, implying that these might contribute to a specific phenotype, further suggesting that MG may be considered an umbrella term that covers several clinical entities.<\/jats:p>","DOI":"10.25122\/jml-2020-0145","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T03:56:51Z","timestamp":1618545411000},"page":"7-16","source":"Crossref","is-referenced-by-count":172,"title":["The epidemiology of myasthenia gravis"],"prefix":"10.25122","volume":"14","author":[{"given":"Ana-Maria","family":"Bubuioc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Neurology, Nicolae Testemitanu State University of Medicine and Pharmacy Chisinau, the Republic of Moldova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Neurology, Nicolae Testemitanu State University of Medicine and Pharmacy Chisinau, the Republic of Moldova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aigerim","family":"Kudebayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Neurology, Kazakh Medical University of Continuing Education, Almaty, Kazakhstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saule","family":"Turuspekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Nervous Diseases with course of Neurosurgery, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitalie","family":"Lisnic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Vitalie Lisnic, MD, PhD, Professor, Department of Neurology, Nicolae Testemitanu State University of Medicine and Pharmacy, 2 Korolenko str., MD \u2013 2028, Chisinau, the Republic of Moldova. Fax: +373-022737200. Phone: +373-79456641. E-mail: vitalie.lisnic@usmf.md","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio Angelo","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Neurology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10755","published-online":{"date-parts":[[2021,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"1. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10.","DOI":"10.1186\/1471-2377-10-46"},{"key":"ref2","unstructured":"2. Gilhus NE. Autoimmune myasthenia gravis. 2009; 9(3):351\u20138."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"3. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle and Nerve. 2004; 29(4):484\u2013505.","DOI":"10.1002\/mus.20030"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"4. Gilhus NE, Verschuuren JJ. Myasthenia gravis\u00a0: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol. 2004;24(1):17\u201320.","DOI":"10.1055\/s-2004-829593"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6. Avidan N, Le Panse R, Berrih-Aknin S, Miller A. Genetic basis of myasthenia gravis - A comprehensive review. J Autoimmun. 2014;52:146\u201353.","DOI":"10.1016\/j.jaut.2013.12.001"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"7. Joensen P. Myasthenia gravis incidence in a general North Atlantic isolated population. Acta Neurol Scand. 2014;130(4):222\u20138.","DOI":"10.1111\/ane.12270"},{"key":"ref8","unstructured":"8. Nel M, Heckmann JM. Myasthenia Gravis and Related Disorders. Myasthenia Gravis Relat Disord. 2018."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9. Bettini M, Chaves M, Cristiano E, Pagotto V, Perez L, Giunta D,\n                      et al.\n                      Incidence of Autoimmune Myasthenia Gravis in a Health Maintenance Organization in Buenos Aires, Argentina. Neuroepidemiology. 2017;48(3\u20134):119\u201323.","DOI":"10.1159\/000477733"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. Gattellari M, Goumas C, Worthington JM. A national epidemiological study of Myasthenia Gravis in Australia. Eur J Neurol. 2012;19(11):1413\u201320.","DOI":"10.1111\/j.1468-1331.2012.03698.x"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. Cetin H, F\u00fcl\u00f6p G, Zach H, Auff E, Zimprich F. Epidemiology of myasthenia gravis in Austria: Rising prevalence in an ageing society. Wien Klin Wochenschr. 2012;124(21\u201322):763\u20138.","DOI":"10.1007\/s00508-012-0258-2"},{"key":"ref12","unstructured":"12. Likhachev SA, Kulikova SL, Astapenko A V. Epidemiology of myasthenia gravis in the Republic of Belarus. Zhurnal Nevrol i Psihiatr Im SS Korsakova. 2014;2014(1):54\u20137."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13. Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord. 2016;26(1):41\u20136.","DOI":"10.1016\/j.nmd.2015.10.009"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. Cea G, Martinez D, Salinas R, Vidal C, Hoffmeister L, Stuardo A. Clinical and epidemiological features of myasthenia gravis in Chilean population. Acta Neurol Scand. 2018;138(4):338\u201343.","DOI":"10.1111\/ane.12967"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15. Fang W, Li Y, Mo R, Wang J, Qiu L, Ou C,\n                      et al.\n                      Hospital and healthcare insurance system record\u2013based epidemiological study of myasthenia gravis in southern and northern China. Neurol Sci. 2020;41(5):1211\u201323.","DOI":"10.1007\/s10072-019-04146-1"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16. Lobjanidze N, Kvirkvelia N, Janelidze M, Jibladze M, Shakarishvili R, Beridze M. PO09-MO-03 The pilot epidemiological study of myasthenia bravis in Republic of Georgia. J Neurol Sci. 2009;285:S192.","DOI":"10.1016\/S0022-510X(09)70739-7"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17. Foldvari A, Kovacs N, Sipos V, Merth G, Vincze F, Szucs M,\n                      et al.\n                      Estimation of incidence, prevalence, and age-at-diagnosis of myasthenia gravis among adults by hospital discharge records. Wien Klin Wochenschr. 2015;127(11\u201312):459\u201364.","DOI":"10.1007\/s00508-015-0796-5"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"18. Lefter S, Hardiman O, Ryan AM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology. 2017;88(3):304\u201313.","DOI":"10.1212\/WNL.0000000000003504"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19. Lotan I, Benninger F, Hellmann MA, Sicsic C, Brenner T, Kahana E,\n                      et al.\n                      Incidence of AChR Ab-positive myasthenia gravis in Israel: A population-based study. Acta Neurol Scand. 2020;142(1):66\u201373.","DOI":"10.1111\/ane.13239"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20. Montomoli C, Citterio A, Piccolo G, Cioccale R, Ferretti V V., Fratti C,\n                      et al.\n                      Epidemiology and geographical variation of myasthenia gravis in the province of Pavia, Italy. Neuroepidemiology. 2012;38(2):100\u20135.","DOI":"10.1159\/000336002"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"21. Sardu C, Cocco E, Mereu A, Massa R, Cuccu A, Marrosu MG,\n                      et al.\n                      Population based study of 12 autoimmune diseases in sardinia, italy: Prevalence and comorbidity. PLoS One. 2012;7(3).","DOI":"10.1371\/journal.pone.0032487"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"22. Pallaver F, Riviera AP, Piffer S, Ricciardi R, Roni R, Orrico D,\n                      et al.\n                      Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years. Neuroepidemiology. 2011;36(4):282\u20137.","DOI":"10.1159\/000328863"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"23. Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H,\n                      et al.\n                      Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci. 2011;305(1\u20132):97\u2013102.","DOI":"10.1016\/j.jns.2011.03.004"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"24. Park SY, Lee JY, Lim NG, Hong YH. Incidence and prevalence of myasthenia gravis in korea: A population-based study using the national health insurance claims database. J Clin Neurol. 2016;12(3):340\u20134.","DOI":"10.3988\/jcn.2016.12.3.340"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"25. Zieda A, Ravina K, Glazere I, Pelcere L, Naudina MS, Liepina L,\n                      et al.\n                      A nationwide epidemiological study of myasthenia gravis in Latvia. Eur J Neurol. 2018;25(3):519\u201326.","DOI":"10.1111\/ene.13535"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"26. Boldingh, M. I., Maniaol, A., Brunborg, C., Dekker, L., Lipka, A., Niks, E. H., \u2026 Tallaksen C. Prevalence and clinical aspects of immigrants with Myasthenia Gravis in northern Europe. Muscle Nerve. 2017;55(6):819\u201327.","DOI":"10.1002\/mus.25408"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"27. Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand. 2014;129(S198):26\u201331.","DOI":"10.1111\/ane.12233"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"28. Santos E, Coutinho E, Moreira I, Silva AM\n                      et al.\n                      Epidemiology of Myasthenia Gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases. Muscle & Nerve. 2016;34.","DOI":"10.1002\/mus.25068"},{"key":"ref29","unstructured":"29. Romanova T. V. Samara epidemiological research of myasthenia gravis. Saratov J Med Sci Res. 2012;8(1):91\u20135."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"30. Martinka I, Fulova M, Spalekova M, Spalek P. Epidemiology of Myasthenia Gravis in Slovakia in the Years 1977\u20132015. Neuroepidemiology. 2018;50(3\u20134):153\u20139.","DOI":"10.1159\/000487886"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"31. Mombaur B, Lesosky MR, Liebenberg L, Vreede H, Heckmann JM. Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa. Muscle and Nerve. 2015;51(4):533\u20137.","DOI":"10.1002\/mus.24348"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"32. Aragon\u00e8s JM, Altimiras J, Roura P, Alonso F, Bufill E, Munmany A,\n                      et al.\n                      Prevalence of myasthenia gravis in the Catalan county of Osona. Neurol (English Ed. 2017;32(1):1\u20135.","DOI":"10.1016\/j.nrleng.2014.09.010"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"33. Fang F, Sveinsson O, Thormar G, Granqvist M, Askling J, Lundberg IE,\n                      et al.\n                      The autoimmune spectrum of myasthenia gravis: A Swedish population-based study. J Intern Med. 2015;277(5):594\u2013604.","DOI":"10.1111\/joim.12310"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"34. Westerberg E, Punga AR. Epidemiology of Myasthenia Gravis in Sweden 2006\u20132016. Brain Behav. 2020;(August):1\u201311.","DOI":"10.1002\/brb3.1819"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"35. Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in Taiwan. Neuroepidemiology. 2010;35(1):66\u201371.","DOI":"10.1159\/000311012"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"36. Maharaj J, Bahadursingh S, Ramcharan K. Myasthenia gravis in South Trinidad. West Indian Med J. 2013;62(6):510\u20134.","DOI":"10.7727\/wimj.2012.105"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"37. Marcoci C, Lisnic V, Gavriliuc M, Odainic O, Sangheli M, Belenciuc A,\n                      et al.\n                      Prevalence of Multiple Sclerosis in the Republic of Moldova. Neuroepidemiology. 2016;46(3):166\u201372.","DOI":"10.1159\/000443931"},{"key":"ref38","unstructured":"38. Turuspekova ST, Nurguzhaev YS, Nurzhanova R., Demesinova BK, Kudebayeva AZ. Myasthenia gravis: current state of research. Chelovek i Lek \u2013 Kazakhstan. 2020;(9 (136)):76."},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"39. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle and Nerve. 2008;37(2):141\u20139.","DOI":"10.1002\/mus.20950"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"40. Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology. 1996;47(5):1233\u20138.","DOI":"10.1212\/WNL.47.5.1233"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"41. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009;72(18):1548\u201354.","DOI":"10.1212\/WNL.0b013e3181a41211"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"42. Owe JF, Daltveit AK, Gilhus NE. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J Neurol Neurosurg Psychiatry. 2006;77(2):203\u20137.","DOI":"10.1136\/jnnp.2005.072355"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"43. Peragallo JH, Bitrian E, Kupersmith MJ, Zimprich F, Whittaker TJ, Lee MS,\n                      et al.\n                      Relationship between age, gender, and race in patients presenting with myasthenia gravis with only ocular manifestations. J Neuro-Ophthalmology. 2016;36(1):29\u201332.","DOI":"10.1097\/WNO.0000000000000276"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"44. Phillips LH, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42(10):1888\u201393.","DOI":"10.1212\/WNL.42.10.1888"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"45. Heckmann JM, Owen EP, Little F. Myasthenia gravis in South Africans: Racial differences in clinical manifestations. Neuromuscul Disord. 2007;17(11\u201312):929\u201334.","DOI":"10.1016\/j.nmd.2007.07.002"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"46. Meyer A, Levy Y. Chapter 33: Geoepidemiology of myasthenia gravis. Autoimmun Rev. 2010;9(5):A383\u20136.","DOI":"10.1016\/j.autrev.2009.11.011"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"47. Asmail A, Kesler A, Drory VE, Kolb H, Karni A. Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel. J Neuroimmunol. 2017;307:47\u201352.","DOI":"10.1016\/j.jneuroim.2017.04.003"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"48. Seybold ME, Lindstrom JM. Myasthenia gravis in infancy. Neurology. 1981 Apr 1;31(4):476 LP \u2013 476.","DOI":"10.1212\/WNL.31.4.476"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"49. Matsui N, Nakane S, Nakagawa Y, Kondo K, Mitsui T, Matsumoto T,\n                      et al.\n                      Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J Neurol Neurosurg Psychiatry. 2009;80(10):1168\u201371.","DOI":"10.1136\/jnnp.2008.152637"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"50. Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A,\n                      et al.\n                      Prognosis of myasthenia gravis: A multicenter follow-up study of 844 patients. J Neurol Sci. 1991;106(2):213\u201320.","DOI":"10.1016\/0022-510X(91)90260-E"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"51. Da Silva JAP. Sex hormones and glucocorticoids: Interactions with the immune system. Vol. 876, Annals of the New York Academy of Sciences. 1999. p. 102\u201318.","DOI":"10.1111\/j.1749-6632.1999.tb07628.x"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"52. Lopomo A, Berrih-Aknin S. Autoimmune thyroiditis and myasthenia gravis. Front Endocrinol (Lausanne). 2017;8(JUL):1\u20138.","DOI":"10.3389\/fendo.2017.00169"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"53. Delpy L, Douin-Echinard V, Garidou L, Bruand C, Saoudi A, Gu\u00e9ry J-C. Estrogen Enhances Susceptibility to Experimental Autoimmune Myasthenia Gravis by Promoting Type 1-Polarized Immune Responses. J Immunol. 2005;175(8):5050\u20137.","DOI":"10.4049\/jimmunol.175.8.5050"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"54. Leker RR, Karni A, Abramsky O. Exacerbation of myasthenia gravis during the menstrual period. J Neurol Sci. 1998;156(1):107\u201311.","DOI":"10.1016\/S0022-510X(98)00031-8"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"55. Nancy P, Berrih-Aknin S. Differential estrogen receptor expression in autoimmune myasthenia gravis. Endocrinology. 2005;146(5):2345\u201353.","DOI":"10.1210\/en.2004-1003"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"56. Zhong H, Zhao C, Luo S. HLA in myasthenia gravis: From superficial correlation to underlying mechanism. Autoimmun Rev. 2019;18(9).","DOI":"10.1016\/j.autrev.2019.102349"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"57. Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA,\n                      et al.\n                      A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015;72(4):396\u2013404.","DOI":"10.1001\/jamaneurol.2014.4103"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"58. Bergoffen J, Zmijewski CM, Fischbeek KH. Familial autoimmune myasthenia gravis. Neurology. 1994 Mar 1;44(3 Part 1):551 LP \u2013 551.","DOI":"10.1212\/WNL.44.3_Part_1.551"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"59. Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE, Nacu A,\n                      et al.\n                      Complicating autoimmune diseases in myasthenia gravis\u00a0: a review. 2015;6934.","DOI":"10.3109\/08916934.2015.1030614"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"60. Fern\u00e1ndez-Mestre MT, Vargas V, Montagnani S, Cot\u00faa M, Ogando V, Layrisse Z. HLA Class II and class I polymorphism in venezuelan patients with myasthenia gravis. Hum Immunol. 2004;65(1):54\u20139.","DOI":"10.1016\/j.humimm.2003.10.003"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"61. Saruhan-Direskeneli G, Kili\u00e7 A, Parman Y, Serdaro\u01e7lu P, Deymeer F. HLA-DQ Polymorphism in Turkish Patients With Myasthenia Gravis. Hum Immunol. 2006;67(4\u20135):352\u20138.","DOI":"10.1016\/j.humimm.2006.02.039"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"62. Whitacre CC. Sex Differences in Autoimmune Disease. Nat Immunol. 2001;2(9):777\u201380.","DOI":"10.1038\/ni0901-777"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"63. Restivo DA, Centonze D, Alesina A, Marchese-Ragona R. Myasthenia Gravis Associated With SARS-CoV-2 Infection. Ann Intern Med. 2020;2(August):2019\u201320.","DOI":"10.7326\/L20-0845"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"64. Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L,\n                      et al.\n                      COVID-19 in patients with myasthenia gravis. Muscle and Nerve. 2020;62(2):254\u20138.","DOI":"10.1002\/mus.26918"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"65. Nemet AY, Kaiserman I, Mimouni M, Segal O, Vinker S. High prevalence of myasthenia gravis among rural adult populations. J Clin Neuromuscul Dis. 2014;16(2):47\u201350.","DOI":"10.1097\/CND.0000000000000054"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"66. Samih M, Ahami AOT. Excessive pesticide use likely to cause the onset of Myasthenia gravis in the Moroccan agricultural population. Pakistan J Biol Sci. 2020;23(7):917\u201321.","DOI":"10.3923\/pjbs.2020.917.921"}],"container-title":["Journal of Medicine and Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medandlife.org\/wp-content\/uploads\/3.-jml-2020-0145-interactive.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T03:59:18Z","timestamp":1618545558000},"score":1,"resource":{"primary":{"URL":"https:\/\/medandlife.org\/wp-content\/uploads\/3.-jml-2020-0145-interactive.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["JMedLife-14-7"],"URL":"https:\/\/doi.org\/10.25122\/jml-2020-0145","relation":{},"ISSN":["1844-122X","1844-3117"],"issn-type":[{"value":"1844-122X","type":"print"},{"value":"1844-3117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}